T-ACE Medical Co., Ltd. worked with T-Top CRO and VCRO to submit T-ACE Oil for clinical trial review to the US FDA. In September 2020, it passed the US FDA’s IND and entered the clinical discussion stage.
T-ACE Oil is an angiographic contrast agent. It used in tandem with trans-arterial chemo-embolization (TACE) for liver cancer; not only does it serve as a vehicle for carrying drug, but it can also be used to help visualize lesions in the liver through x-ray.